Antifungal

SCYNEXIS Announces FDA Approval of BREXAFEMME® (ibrexafungerp tablets) as the First and Only Oral Non-Azole Treatment for Vaginal Yeast Infections

Retrieved on: 
Wednesday, June 2, 2021
Branches of biology, Medical specialties, Infectious diseases, Yeasts, Gut flora, Pathogenic microbes, Cándida, Vaginal yeast infection, Candidiasis, VVC, Antifungal, Chloroarenes

The FDA approval of BREXAFEMME is the culmination of years of work and a significant milestone for SCYNEXIS, marking our evolution to a commercial-stage antifungal company.

Key Points: 
  • The FDA approval of BREXAFEMME is the culmination of years of work and a significant milestone for SCYNEXIS, marking our evolution to a commercial-stage antifungal company.
  • BREXAFEMME has a differentiated fungicidal mechanism of action that kills a broad range of Candida species, including azole-resistant strains.
  • BREXAFEMME is the trade name for ibrexafungerp, a novel oral antifungal approved for the treatment of vulvovaginal candidiasis (VVC), also known as vaginal yeast infection.
  • BREXAFEMME represents the first approved drug in a new antifungal class in over 20 years and is the first and only treatment for vaginal yeast infections which is both oral and non-azole.

Global Antifungal Drugs Market to Surpass US$ 16.2 Billion by 2028, Says Coherent Market Insights (CMI)

Retrieved on: 
Monday, May 24, 2021
General Health, Consulting, Health, Professional services, Pharmaceutical, Antifungal, Forecast period

According to Coherent Market Insights, the global antifungal drugs market is estimated to be valued at US$ 13.1 billion in 2021 and is expected to exhibit a CAGR of 3.1% during the forecast period (2021-2028).

Key Points: 
  • According to Coherent Market Insights, the global antifungal drugs market is estimated to be valued at US$ 13.1 billion in 2021 and is expected to exhibit a CAGR of 3.1% during the forecast period (2021-2028).
  • Increasing product approvals by the regulatory authorities is expected to drive the growth of the global antifungal drugs market over the forecast period.
  • Increasing prevalence of fungal infections among the global population is expected to increase the growth of the global antifungal drugs market over the forecast period.
  • Among regions, North America is expected to hold a dominant position in the global antifungal drugs market over the forecast period, owing to increasing launches of antifungal drugs.

HeiQ launches high-tech mask featuring ground-breaking copper technology shown to deactivate the COVID-19 virus in five minutes

Retrieved on: 
Wednesday, May 5, 2021
Health, Medicine, Biocides, Antiviral drug, Surgical mask, Antifungal, Copper, Virus, Antibiotic, Bacteria

HeiQ MetalliX is a patent-pending technology, created by HeiQ\'s innovation partner,Australian materials technology company, Xefco.

Key Points: 
  • HeiQ MetalliX is a patent-pending technology, created by HeiQ\'s innovation partner,Australian materials technology company, Xefco.
  • The antiviral, antibacterial and antifungal properties of copper have been known for centuries and have been demonstrated by many laboratory studies.
  • HeiQ MetalliX treated materials release copper ions which deactivate viruses and bacteria.
  • Further, it gives an edgy look, making it an improved alternative to surgical masks in many ways," says Carlo Centonze, co-founder and CEO of HeiQ Group.\n'

HeiQ launches high-tech mask featuring ground-breaking copper technology shown to deactivate the COVID-19 virus in five minutes

Retrieved on: 
Wednesday, May 5, 2021
Health, Medicine, Biocides, Antiviral drug, Surgical mask, Antifungal, Copper, Virus, Antibiotic, Bacteria

HeiQ MetalliX is a patent-pending technology, created by HeiQ\'s innovation partner,Australian materials technology company, Xefco.

Key Points: 
  • HeiQ MetalliX is a patent-pending technology, created by HeiQ\'s innovation partner,Australian materials technology company, Xefco.
  • The antiviral, antibacterial and antifungal properties of copper have been known for centuries and have been demonstrated by many laboratory studies.
  • HeiQ MetalliX treated materials release copper ions which deactivate viruses and bacteria.
  • Further, it gives an edgy look, making it an improved alternative to surgical masks in many ways," says Carlo Centonze, co-founder and CEO of HeiQ Group.\n'

Cidara Therapeutics Appoints Biotechnology Industry Veteran Christopher Kurtz As Executive Vice President of Technical Operations

Retrieved on: 
Tuesday, December 15, 2020
Biocides, AbbVie, Companies, Antiviral drug, Antifungal, Health care, Health sciences

SAN DIEGO, Dec. 15, 2020 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today announced the appointment of Christopher (Chris) Kurtz as executive vice president of technical operations.

Key Points: 
  • SAN DIEGO, Dec. 15, 2020 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today announced the appointment of Christopher (Chris) Kurtz as executive vice president of technical operations.
  • We are pleased to welcome Chris to our leadership team at such a pivotal time for our antifungal and antiviral programs, said Jeffrey Stein, Ph.D., president and chief executive officer of Cidara.
  • He previously served as vice president, for drug device industrialization at AbbVie, where he led product scale-up and industrialization projects for drug-device combinations.
  • Cidara is developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections.

SCYNEXIS Announces FDA Acceptance and Priority Review of New Drug Application for Oral Ibrexafungerp for the Treatment of Vaginal Yeast Infections

Retrieved on: 
Monday, December 7, 2020
Health, Vagina, Vaginal yeast infection, Prescription Drug User Fee Act, Food and Drug Administration, Candidiasis, Antifungal, VVC, Infection, Infectious disease, Lipoglycopeptide

Under the Prescription Drug User Fee Act (PDUFA), the FDA has set a target action date of June 1, 2021.

Key Points: 
  • Under the Prescription Drug User Fee Act (PDUFA), the FDA has set a target action date of June 1, 2021.
  • "As the first oral, non-azole treatment for this particularly symptomatic condition, we believe ibrexafungerp has the potential to change the antifungal treatment landscape.
  • Ibrexafungerp benefits from both Qualified Infectious Disease Product (QIDP) and Fast Track designations granted by the FDA for the treatment of VVC and prevention of recurrent VVC.
  • It is currently under review by the FDA as a treatment for vaginal yeast infections and in late-stage development for multiple life-threatening fungal infections in hospitalized patients.

Basilea reports acceptance for regulatory review of Pfizer’s marketing authorization application for antifungal isavuconazole (Cresemba®) in invasive aspergillosis in China

Retrieved on: 
Wednesday, November 25, 2020
Infectious diseases, Medicine, Medical specialties, Astellas Pharma, Isavuconazonium, Nitriles, Prodrugs, Thiazoles, Mucormycosis, Pfizer, Antifungal, Mycosis

In August 2020, Basilea had announced that an MAA for Cresemba for the treatment of mucormycosis was accepted for review by the NMPA.

Key Points: 
  • In August 2020, Basilea had announced that an MAA for Cresemba for the treatment of mucormycosis was accepted for review by the NMPA.
  • China is commercially a very important market for Cresemba, accounting for more than 15 percent of the global market for newer antifungals.
  • We are therefore very pleased with the progress Pfizer is making in China.
  • The acceptance of the isavuconazole marketing authorization applications for regulatory review is an important milestone in bringing Cresemba to the Chinese market and addressing the unmet medical needs of patients suffering from invasive mold infections.

SCYNEXIS to Participate in Piper Sandler and Evercore ISI Conferences

Retrieved on: 
Tuesday, November 24, 2020
Infectious diseases, Medical specialties, Branches of biology, Antifungal, Vaginal yeast infection, Candidiasis, Mycosis, Medication, Vagina

A webcast of both presentation recordings will be available for 30 days and can be found on the Scynexis website at: https://www.scynexis.com/news-media/events .

Key Points: 
  • A webcast of both presentation recordings will be available for 30 days and can be found on the Scynexis website at: https://www.scynexis.com/news-media/events .
  • SCYNEXIS, Inc.(NASDAQ: SCYX) is a biotechnology company pioneering innovative medicines to potentially help millions of patients worldwide overcome and prevent difficult-to-treat infections that are becoming increasingly drug-resistant.
  • Our lead candidate,ibrexafungerp (formerly known as SCY-078), is a broad-spectrum, IV/oral antifungal agent representing a novel therapeutic class, in late stage development for multiple indications, ranging from vaginal yeast infections to life-threatening fungal infections in hospitalized patients.
  • The SCYNEXIS team has deep expertise in anti-infective drug development and marketing, which can be leveraged to advance ibrexafungerp from clinical development to commercialization.

Cidara Therapeutics to Participate in Two Upcoming Investor Conferences

Retrieved on: 
Wednesday, November 11, 2020
Biocides, Antiviral drug, Infectious diseases, Infection, Antifungal, Medical specialties, Influenza, Health sciences

Panel Discussion - No Fungus Among Us: Addressing an Important Fungal Need

Key Points: 
  • Panel Discussion - No Fungus Among Us: Addressing an Important Fungal Need
    Cidara is developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections.
  • The Companys portfolio is comprised of its lead antifungal candidate, rezafungin, in addition to antiviral conjugates (AVCs) for the prevention and treatment of influenza and other viral diseases from Cidaras proprietary Cloudbreak antiviral platform.
  • Cidara is headquartered in San Diego, California.
  • For more information, please visit www.cidara.com .

SCYNEXIS to Present Two Posters Highlighting Ibrexafungerp for the Treatment of Vaginal Yeast Infection at the 23rd Annual Premier Women's Healthcare Virtual Conference

Retrieved on: 
Monday, October 12, 2020
RTT, Medical specialties, Infectious diseases, Clinical medicine, Vaginal yeast infection, Candidiasis, Fluconazole, Cándida, VVC, Vagina, Antifungal, Azole

The posters will highlight the robust Phase 3 data on ibrexafungerp, a novel broad-spectrum antifungal, as a treatment for vulvovaginal candidiasis (VVC), also known as vaginal yeast infection, as well as its potency against multiple strains of Candida, including strains resistant to fluconazole.

Key Points: 
  • The posters will highlight the robust Phase 3 data on ibrexafungerp, a novel broad-spectrum antifungal, as a treatment for vulvovaginal candidiasis (VVC), also known as vaginal yeast infection, as well as its potency against multiple strains of Candida, including strains resistant to fluconazole.
  • Vaginal yeast infection occurs in the majority of women at least once in their lifetime.
  • For over twenty years, azoles have been the only class of treatments available for women suffering from vaginal yeast infections.
  • Women have been underserved with limited treatments and as a result we are observing an increase in resistance to the azole drug class.